The nuchal fold (NF) thickness is a measurement performed on prenatal ultrasound, and is the distance from the outer edge of the occipital bone to the outer edge of the skin in the midline. While both measurements are at the level of the fetal head or neck, a nuchal fold thickness, which is only performed in the second trimester, should not be confused with a first trimester nuchal translucency (NT) measurement.
If an enlarged second trimester nuchal fold measurement is obtained, next steps should include:
Second trimester thickened nuchal fold has a high specificity for aneuploidy. ACOG defines an abnormal nuchal fold as ≥ 6mm in the 2nd trimester (typically performed between 15w0d and 22w6d). The SOGC (Society of Obstetricians and Gynecologists of Canada) considers a nuchal fold to be abnormal when the measurement is ≥ 5 mm at 16-18 weeks, or ≥ to 6 mm at 18-24 weeks. It is the most powerful second trimester sonographic marker for Trisomy 21 / Down syndrome.
ACOG Practice Bulletin 226: Screening for Fetal Chromosomal Abnormalities
SOGC: Fetal Soft Markers in Obstetric Ultrasound
ACOG Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders
Take a post-test and get CME credits
Please log in to ObGFirst to access the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
